Editorial: Does diabetes therapy influence the risk of cancer?

Diabetologia

Volumn 52, Issue 9, 2009, Pages 1699-1708

  Smith, U ^a   Gale, E A M ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Cancer; Insulin analogues; Insulin therapy; Metformin; Type 2 diabetes

Indexed keywords

CYCLIN D1; HEPATOCYTE NUCLEAR FACTOR 1BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; ROSIGLITAZONE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SULFONYLUREA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; DRUG DERIVATIVE; INSULIN RECEPTOR; RECOMBINANT PROTEIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER REGISTRY; CANCER RISK; CARCINOGENICITY; CD8+ T LYMPHOCYTE; CELL STRAIN MCF 7; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MORTALITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SCANNING ELECTRON MICROSCOPY; SMOKING; SWEDEN; UNITED KINGDOM; ANIMAL; BREAST TUMOR; COLON TUMOR; FEMALE; GENETICS; INSULIN RESISTANCE; MALE; MOLECULAR EVOLUTION; NEOPLASM; NOTE; PANCREAS TUMOR; PROSTATE TUMOR; RISK FACTOR; RODENT; ULTRASTRUCTURE;

ANIMALS; BREAST NEOPLASMS; COLONIC NEOPLASMS; DIABETES MELLITUS, TYPE 2; EVOLUTION, MOLECULAR; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; MALE; NEOPLASMS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; RECOMBINANT PROTEINS; RISK FACTORS; RODENTIA;

EID: 68449088664     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-009-1441-5     Document Type: Editorial

References (54)

1. SS Coughlin 2004 Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults Am J Epidemiol 159 1160 1167
2. SC Larsson N Orsini A Wolk 2005 Diabetes mellitus and risk of colorectal cancer: a meta-analysis J Natl Cancer Inst 97 1679 1687 (Pubitemid 41672234)
3. R Huxley A Ansary-Moghaddam A Berrington de Gonzalez F Barzi M Woodward 2005 Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies Br J Cancer 92 2076 2083
4. SC Larsson CS Mantzoros A Wolk 2007 Diabetes mellitus and risk of breast cancer: a meta-analysis Int J Cancer 121 856 862
5. K Zendehdel O Nyrén C-G Östenson H-O Adami A Ekbom W Ye 2003 Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden J Natl Cancer Inst 95 1797 1800 (Pubitemid 38008903)
6. E Giovannucci D Michaud 2007 The role of obesity and related metabolic disturbances in cancers of the colon, prostate and pancreas Gastroenterology 132 2208 2225
7. HE Mulnier HE Seaman VS Raleigh SS Soedamah-Muthu HM Colhoun RA Lawrenson 2006 Mortality in people with type 2 diabetes in the UK Diabetic Med 23 516 521
8. JMM Evans LA Donnelly AM Emslie-Smith DR Alessi AD Morris 2005 Metformin and reduced risk of cancer in diabetic patients BMJ 330 1304 1305
9. SL Bowker 2006 Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin Diabetes Care 29 254 258
10. Currie CJ, Poole CD, Gale EAM (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia doi: 10.1007/s00125-009-1440-6
11. M Zakikhani R Dowling IG Fantus N Sonenberg M Pollak 2006 Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells Cancer Res 66 10269 10273
12. G Schimmack RA DeFronzo N Musi 2006 AMP-activated protein kinase: role in metabolism and therapeutic implications Diabetes Obes Metab 8 591 602
13. IB Sahra K Laurent A Loubat 2008 The antidiabetic drug metformin exerts an antitumour effect in vitro and in vivo through a decrease in cyclin D1 level Oncogene 27 3576 3586
14. EL Pearce MC Walsh PJ Cejas 2009 Enhancing CD8 T cell memory by modulating fatty acid metabolism Nature 10.1038/nature08097
15. Y-X Yang S Hennessy JD Lewis 2004 Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients Gastroenterology 127 1044 1050
16. IR Hsu SP Kim M Kabir RN Bergman 2007 Metabolic syndrome, hyperinsulinemia, and cancer Am J Clin Nutr 86 867S 871S
17. JMP Holly CM Perks 2008 Cancer as an endocrine problem Best Pract Res Clin Endocrinol Metab 22 539 550
18. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70
19. AA Samani S Yakar D LeRoith P Brodt 2007 The role of the IGF system in cancer growth and metastasis: overview and recent insights Endocr Rev 28 20 47
20. JJ Kim D Accili 2002 Signalling through IGF-1 and insulin receptors: where is the specificity? Growth Horm IGF Res 12 84 90
21. F Frasca G Pandini P Scalia 1999 Insulin receptor isoform A, a newly recognised, high affinity insulin-like growth factor II receptor in fetal and cancer cells Mol Cell Biol 19 3278 3288
22. R Baserga F Peruzzi K Reiss 2003 The IGF-1 receptor in cancer biology Int J Cancer 107 873 877
23. LG Hemkens U Grouven R Bender 2009 Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study Diabetologia 10.1007/s00125-009-1418-4
24. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdò ttir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. doi: 10.1007/s00125-009-1444-2
25. Colhoun HM, SDRN Epidemiology group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. doi: 10.1007/s00125-009-1453-1
26. http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety- RelatedDrugLabelingChanges/ucm122978.htm, accessed 15 June 1009
27. C Mathieu EAM Gale 2008 Inhaled insulin: gone with the wind? Diabetologia 51 1 5
28. M Berger 2000 Safety of insulin glargine Lancet 356 2013
29. P Ebeling JA Tuominen VA Koivisto 1996 Insulin analogues and carcinoma of the breast Diabetologia 39 124 125
30. BF Hansen GM Danielsen K Drejer 1996 Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency Biochem J 315 271 279
31. LJ Slieker GS Brooke RD DiMarchi 1997 Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-1 receptor more than for the insulin receptor Diabetologia 40 S54 S61
32. Jorgensen L, Dideriksen L, Drejer K (1992) Carcinogenic effect of the human insulin analogue B10Asp in female rats. Diabetologia 35(Suppl 1):A3 (Abstract)
33. P Kurtzhals L Schäffer A Sørensen 2000 Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use Diabetes 49 999 1005
34. S Erbel MW Büchler C Reers 2008 Proliferation of Colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine Diabetes Care 31 1105 1111
35. D Weinstein M Simon E Yehezkel Z Laron H Werner 2008 Insulin analogues display IGF-1-like mitogenic and anti-apoptotic activities in cultured cancer cells Diabetes Metab Res Rev 25 41 49
36. A Shukla J Grisouard V Ehemann A Hermani H Enzmann D Mayer 2009 Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines Endocr Relat Cancer 16 429 441
37. GU Kuerzel U Shukla HE Scholtz 2003 Biotransformation of insulin glargine after subcutaneous injection in healthy subjects Curr Med Res Opin 19 34 40
38. A Agin N Jeandidier F Gasser D Grucker R Sapin 2007 Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay Diabetes Metab 33 205 212
39. I Stammberger A Bube B Durchfeld-Meyer H Donaubauer G Troschau 2002 Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice Int J Toxicol 21 171 179 (Pubitemid 34803492)
40. http://www.drugs.com/pro/lantus.html, accessed 15 June 2009
41. J Rosenstock V Fonseca JB McGill 2009 Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study Diabetologia 10.1007/s00125-009-1415-7
42. MB Schneider H Matsuzaki J Haorah 2001 Prevention of pancreatic cancer induction in hamsters by metformin Gastroenterology 120 1263 1270
43. AV Matveyenko S Dry HI Cox 2009 Beneficial endocrine but adverse exocrine effects of sitagliptin in the HIP rat model of type 2 diabetes, interactions with metformin Diabetes 10.2337/db09-0058 (Epub ahead of print)
44. J Rosenstock SL Schwartz CM Clark Jr GD Park DW Donley MB Edwards 2001 Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin Diabetes Care 24 631 636
45. I Zib P Raskin 2006 Novel insulin analogues and its mitogenic potential Diabetes Obes Metab 8 611 620
46. LC Shaw MB Grant 2004 Insulin like growth factor-1 and insulin-like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology Rev Endocr Metab Disord 5 199 207
47. N Black 1996 Why we need observational studies BMJ 312 1215 1218
48. PN Papanikolaou GD Christidi JP Ioannidis 2006 Comparision of evidence on harms of medical interventions in randomized and non-randomized studies CMAJ 174 635 641
49. F Holleman EAM Gale 2007 Nice insulins, pity about the evidence Diabetologia 50 1783 1790
50. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW et al (2007) Long-acting insulin analogues vs NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev issue 2:art. no. CD005613. doi: 10.1002/14651858.CD005613.pub3. (Pubitemid 351805825)
51. DM Nathan JM Buse MB Davidson 2009 Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 52 17 30
52. SR Singh F Ahmad A Lal C Yu Z Bai H Bennett 2009 Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis CMAJ 180 385 397
53. BB Barone H-C Yeh CF Snyder 2008 Long-term all-cause mortality in cancer patients with pre-existing diabetes mellitus. A systematic review and meta-analysis JAMA 300 2754 2764
54. TM Frayling H Colhoun JC Florez 2008 A genetic link between type 2 diabetes and prostate cancer Diabetologia 51 1757 1760